Logo image of SRXH

SRX HEALTH SOLUTIONS INC (SRXH) Stock Fundamental Analysis

USA - NYSEARCA:SRXH - US08771Y4026 - Common Stock

0.3493 USD
0 (-0.88%)
Last: 10/3/2025, 8:05:15 PM
0.355 USD
+0.01 (+1.63%)
After Hours: 10/3/2025, 8:05:15 PM
Fundamental Rating

4

SRXH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 39 industry peers in the Consumer Staples Distribution & Retail industry. The financial health of SRXH is average, but there are quite some concerns on its profitability. SRXH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SRXH had negative earnings in the past year.
SRXH had a negative operating cash flow in the past year.
In the past 5 years SRXH reported 4 times negative net income.
In the past 5 years SRXH reported 4 times negative operating cash flow.
SRXH Yearly Net Income VS EBIT VS OCF VS FCFSRXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of 11.11%, SRXH belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
With a decent Return On Equity value of 21.33%, SRXH is doing good in the industry, outperforming 69.23% of the companies in the same industry.
Industry RankSector Rank
ROA 11.11%
ROE 21.33%
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRXH Yearly ROA, ROE, ROICSRXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

With an excellent Profit Margin value of 4.96%, SRXH belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
Looking at the Gross Margin, with a value of 37.27%, SRXH is in the better half of the industry, outperforming 79.49% of the companies in the same industry.
In the last couple of years the Gross Margin of SRXH has remained more or less at the same level.
Industry RankSector Rank
OM N/A
PM (TTM) 4.96%
GM 37.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
SRXH Yearly Profit, Operating, Gross MarginsSRXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

SRXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRXH has more shares outstanding than it did 1 year ago.
SRXH has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SRXH has an improved debt to assets ratio.
SRXH Yearly Shares OutstandingSRXH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SRXH Yearly Total Debt VS Total AssetsSRXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

SRXH has an Altman-Z score of -27.27. This is a bad value and indicates that SRXH is not financially healthy and even has some risk of bankruptcy.
SRXH has a Altman-Z score of -27.27. This is amonst the worse of the industry: SRXH underperforms 97.44% of its industry peers.
SRXH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.27
ROIC/WACCN/A
WACC7.72%
SRXH Yearly LT Debt VS Equity VS FCFSRXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.99 indicates that SRXH should not have too much problems paying its short term obligations.
SRXH has a better Current ratio (1.99) than 79.49% of its industry peers.
A Quick Ratio of 1.37 indicates that SRXH should not have too much problems paying its short term obligations.
The Quick ratio of SRXH (1.37) is better than 84.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.37
SRXH Yearly Current Assets VS Current LiabilitesSRXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for SRXH have decreased strongly by -1082.17% in the last year.
Looking at the last year, SRXH shows a quite strong growth in Revenue. The Revenue has grown by 18.81% in the last year.
The Revenue has been growing by 671.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1082.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.45%
Revenue 1Y (TTM)18.81%
Revenue growth 3Y51.96%
Revenue growth 5Y671.49%
Sales Q2Q%34.04%

3.2 Future

Based on estimates for the next years, SRXH will show a very strong growth in Earnings Per Share. The EPS will grow by 26.17% on average per year.
SRXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.51% yearly.
EPS Next Y99.22%
EPS Next 2Y41.25%
EPS Next 3Y26.17%
EPS Next 5YN/A
Revenue Next Year12.44%
Revenue Next 2Y87.02%
Revenue Next 3Y63.51%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SRXH Yearly Revenue VS EstimatesSRXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
SRXH Yearly EPS VS EstimatesSRXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRXH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRXH Price Earnings VS Forward Price EarningsSRXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRXH Per share dataSRXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as SRXH's earnings are expected to grow with 26.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.25%
EPS Next 3Y26.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SRX HEALTH SOLUTIONS INC

NYSEARCA:SRXH (10/3/2025, 8:05:15 PM)

After market: 0.355 +0.01 (+1.63%)

0.3493

0 (-0.88%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)09-30 2025-09-30/amc
Earnings (Next)11-10 2025-11-10
Inst Owners1.03%
Inst Owner ChangeN/A
Ins Owners20.55%
Ins Owner Change0%
Market Cap5.38M
Analysts82.86
Price Target10.2 (2820.13%)
Short Float %N/A
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS2.22
BVpS0.52
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 21.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 4.96%
GM 37.27%
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
F-Score5
Asset Turnover2.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.19%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.37
Altman-Z -27.27
F-Score5
WACC7.72%
ROIC/WACCN/A
Cap/Depr(3y)14.78%
Cap/Depr(5y)14.84%
Cap/Sales(3y)0.18%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1082.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.45%
EPS Next Y99.22%
EPS Next 2Y41.25%
EPS Next 3Y26.17%
EPS Next 5YN/A
Revenue 1Y (TTM)18.81%
Revenue growth 3Y51.96%
Revenue growth 5Y671.49%
Sales Q2Q%34.04%
Revenue Next Year12.44%
Revenue Next 2Y87.02%
Revenue Next 3Y63.51%
Revenue Next 5YN/A
EBIT growth 1Y61.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y79.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.34%
OCF growth 3YN/A
OCF growth 5YN/A